305 related articles for article (PubMed ID: 20375197)
1. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
2. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
Hruba L; McMahon LR
Eur J Pharmacol; 2014 Mar; 727():35-42. PubMed ID: 24486701
[TBL] [Abstract][Full Text] [Related]
5. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
Ginsburg BC; Schulze DR; Hruba L; McMahon LR
J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
[TBL] [Abstract][Full Text] [Related]
6. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
Schulze DR; Carroll FI; McMahon LR
Psychopharmacology (Berl); 2012 Aug; 222(3):425-38. PubMed ID: 22374253
[TBL] [Abstract][Full Text] [Related]
7. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
8. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2009 Apr; 203(2):219-28. PubMed ID: 18592221
[TBL] [Abstract][Full Text] [Related]
9. JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.
Rodriguez JS; McMahon LR
Eur J Pharmacol; 2014 Oct; 740():151-9. PubMed ID: 24972243
[TBL] [Abstract][Full Text] [Related]
10. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
12. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
Maguire DR; Yang W; France CP
J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
Wiley JL; Lowe JA; Balster RL; Martin BR
J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
[TBL] [Abstract][Full Text] [Related]
14. Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.
McMahon LR
Drug Alcohol Depend; 2016 Aug; 165():87-93. PubMed ID: 27289270
[TBL] [Abstract][Full Text] [Related]
15. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
Hruba L; McMahon LR
J Pharmacol Exp Ther; 2017 Aug; 362(2):278-286. PubMed ID: 28533288
[TBL] [Abstract][Full Text] [Related]
16. The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.
Stewart JL; McMahon LR
Br J Pharmacol; 2011 Sep; 164(2b):655-66. PubMed ID: 21449917
[TBL] [Abstract][Full Text] [Related]
17. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Li JX; McMahon LR; Gerak LR; Becker GL; France CP
Psychopharmacology (Berl); 2008 Aug; 199(2):199-208. PubMed ID: 18470505
[TBL] [Abstract][Full Text] [Related]
18. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
19. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
20. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
